Zacks Investment Research upgraded shares of TRANZYME INC (TZYM) from NEUTRAL to OUTPERFORM on November 29, 2012, with a target price of $0.80.
Tranzyme Inc. operates as a biopharmaceutical company focused on the development of novel small molecule drugs for the treatment of both acute and chronic disorders. The Company's pipeline lead products, ulimorelin (an i.v. prokinetic agent for postoperative ileus and acute gastric motility disorders) and TZP-102 (an oral prokinetic for gastroparesis) are potent ghrelin agonists.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on TRANZYME INC (TZYM),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment